PMC:7335494 / 28584-28952 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T219","span":{"begin":109,"end":112},"obj":"Body_part"},{"id":"T220","span":{"begin":360,"end":363},"obj":"Body_part"}],"attributes":[{"id":"A219","pred":"fma_id","subj":"T219","obj":"http://purl.org/sig/ont/fma/fma82785"},{"id":"A220","pred":"fma_id","subj":"T220","obj":"http://purl.org/sig/ont/fma/fma82785"}],"text":"2DM females Patients received either 10 g/day inulin or maltodextrin/day for 8 weeks Inulin: ↓CRP, TNF-α and LPS Dehghan et al. (2014a)\nRandomized controlled clinical trial 52 overweight/obese women with T2DM Patients received either 10 g/d of oligofructose-enriched inulin or maltodextrin (control) for 8 weeks oligofructose-enriched-Inulin: ↓ CRP, TNF-α and LPS Dehg"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T285","span":{"begin":4,"end":11},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T286","span":{"begin":173,"end":175},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"}],"text":"2DM females Patients received either 10 g/day inulin or maltodextrin/day for 8 weeks Inulin: ↓CRP, TNF-α and LPS Dehghan et al. (2014a)\nRandomized controlled clinical trial 52 overweight/obese women with T2DM Patients received either 10 g/d of oligofructose-enriched inulin or maltodextrin (control) for 8 weeks oligofructose-enriched-Inulin: ↓ CRP, TNF-α and LPS Dehg"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T326","span":{"begin":46,"end":52},"obj":"Chemical"},{"id":"T327","span":{"begin":56,"end":68},"obj":"Chemical"},{"id":"T328","span":{"begin":85,"end":91},"obj":"Chemical"},{"id":"T329","span":{"begin":109,"end":112},"obj":"Chemical"},{"id":"T332","span":{"begin":267,"end":273},"obj":"Chemical"},{"id":"T333","span":{"begin":277,"end":289},"obj":"Chemical"},{"id":"T334","span":{"begin":335,"end":341},"obj":"Chemical"},{"id":"T335","span":{"begin":360,"end":363},"obj":"Chemical"}],"attributes":[{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_15443"},{"id":"A327","pred":"chebi_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/CHEBI_25140"},{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_15443"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_16412"},{"id":"A330","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_52603"},{"id":"A331","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_89981"},{"id":"A332","pred":"chebi_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/CHEBI_15443"},{"id":"A333","pred":"chebi_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/CHEBI_25140"},{"id":"A334","pred":"chebi_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/CHEBI_15443"},{"id":"A335","pred":"chebi_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/CHEBI_16412"},{"id":"A336","pred":"chebi_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/CHEBI_52603"},{"id":"A337","pred":"chebi_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/CHEBI_89981"}],"text":"2DM females Patients received either 10 g/day inulin or maltodextrin/day for 8 weeks Inulin: ↓CRP, TNF-α and LPS Dehghan et al. (2014a)\nRandomized controlled clinical trial 52 overweight/obese women with T2DM Patients received either 10 g/d of oligofructose-enriched inulin or maltodextrin (control) for 8 weeks oligofructose-enriched-Inulin: ↓ CRP, TNF-α and LPS Dehg"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T62","span":{"begin":176,"end":186},"obj":"Phenotype"}],"attributes":[{"id":"A62","pred":"hp_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/HP_0025502"}],"text":"2DM females Patients received either 10 g/day inulin or maltodextrin/day for 8 weeks Inulin: ↓CRP, TNF-α and LPS Dehghan et al. (2014a)\nRandomized controlled clinical trial 52 overweight/obese women with T2DM Patients received either 10 g/d of oligofructose-enriched inulin or maltodextrin (control) for 8 weeks oligofructose-enriched-Inulin: ↓ CRP, TNF-α and LPS Dehg"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T2061","span":{"begin":46,"end":52},"obj":"PR:000009054"},{"id":"T2062","span":{"begin":300,"end":325},"obj":"CHEBI:47916;CHEBI:47916"}],"text":"2DM females Patients received either 10 g/day inulin or maltodextrin/day for 8 weeks Inulin: ↓CRP, TNF-α and LPS Dehghan et al. (2014a)\nRandomized controlled clinical trial 52 overweight/obese women with T2DM Patients received either 10 g/d of oligofructose-enriched inulin or maltodextrin (control) for 8 weeks oligofructose-enriched-Inulin: ↓ CRP, TNF-α and LPS Dehg"}